FOXA1 Suppresses SATB1 Transcription and Inactivates the Wnt/β-Catenin Pathway to Alleviate Diabetic Nephropathy in a Mouse Model
Hong Zhu,Jiarui Peng,Wei Li
DOI: https://doi.org/10.2147/DMSO.S314709
2021-09-10
Abstract:Hong Zhu, &ast Jiarui Peng, &ast Wei Li Department of Endocrinology, The Third People's Hospital of Yunnan Province, Kunming, 650011, Yunnan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Li Department of Endocrinology, The Third People's Hospital of Yunnan Province, No. 292, Beijing Road, Guandu District, Kunming, 650011, Yunnan, People's Republic of China Tel/Fax +86-871-63194278 Email Objective: Diabetic nephropathy (DN) represents the most common diabetic complication that may lead to end-stage renal disease. This work focused on the effect of FOXA1 on the DN development and the molecular mechanism. Methods: A mouse model of DN was induced by high-fat diets and streptozotocin. The concentrations of blood glucose and urinary protein in mice, and the pathological changes in mouse kidney tissues were determined. A podocyte cell line MPC-5 was treated with high glucose (HG) to mimic a DN-like condition in vitro. FOXA1 and SATB1 were overexpressed in HG-treated MPC-5 cells and in DN mice to explore their effects on cell proliferation and apoptosis, and on pathological changes in mouse kidney tissues. The binding relationship between FOXA1 and STAB1 was predicted and validated. Activation of the Wnt/β-catenin pathway was detected. Results: FOXA1 was poorly expressed in the kidney tissues of DN mice. Overexpression of FOXA1 reduced the concentrations of fasting blood glucose and 24-h urinary protein in mice. It also suppressed the accumulation of glomerular mesangial matrix and hyperplasia of glomerular basement membrane, and reduced collagen deposition and interstitial fibrosis in mouse kidney. Also, FOXA1 reduced HG-induced apoptosis of MPC-5 cells. FOXA1 bound to the promoter region of SATB1 for transcription suppression. Overexpression of SATB1 activated the Wnt/β-catenin pathway and blocked the protective roles of FOXA1 in DN mice and in HG-treated MPC-5 cells. Conclusion: This study demonstrated that FOXA1 transcriptionally suppresses SATB1 expression and inactivates the Wnt/β-catenin signaling pathway, thereby inhibiting podocyte apoptosis and DN progression. Keywords: diabetic nephropathy, FOXA1, SATB1, Wnt/β-catenin, MPC-5 Approximately 20–40% of all diabetic patients may develop diabetic nephropathy (DN) during their disease course, leaving DN the most common diabetic complication and a threat to end-stage renal disease. 1,2 Like many renal diseases, DN is characterized by proteinuria, which is frequently induced by death and loss of podocytes, followed by reduced glomerular filtration, mesangial matrix expansion glomerulosclerosis and the consequent kidney failure. 3,4 Initiation and progression of DN is not always predictable and the DN development is a long-term process occurring gradually over many years. 5 Several mechanisms such as activation of the profibrotic transforming growth factor beta (TGF-β) signaling, 6 suppression in fibroblast growth factor receptor 1 signaling, 7 loss of endothelial glucocorticoid receptor, 8 and dysregulated central metabolism 9 have been reported to be associated with DN development. Glucose-lowering medications such as dipeptidyl peptidase-4 inhibitors 10 and sodium-glucose co-transporter type 2 inhibitors, 11 renin-angiotensin system inhibitors 12 and glycolysis inhibitors 13 have been applied in the treatment of DN. However, there remains an urgent need to explore effective biomarkers for DN predication, and to develop novel treatment options for DN, which requires intensive understanding in the molecular mechanism involved in DN progression. The pathogenesis of DN has been explored extensively. The phenotypic changes in metabolites, proteins, cytokines, and transcription factors are responsible for the accumulation of extracellular matrix and glomerulosclerosis, therefore are key events during DN progression. 14 Forkhead Box A1 (FOXA1), a nuclear transcription factor, is widely distributed in urothelium of the bladder, ureter and renal pelvis. 15 Interestingly, a type 2 diabetes-related genome-wide association study suggested FOXA1 as one of the type 2 diabetes-associated loci, 16 and upregulation of FOXA1 has been demonstrated to suppress damage and apoptosis of podocytes during the process of DN. 17 However, as a transcription factor, its transcriptional regulation during DN development remains unknown. Importantly, the bioinformatics analyses in the study suggested that FOXA1 owned a putative binding relationship with the promoter region of special AT-rich sequence-binding protein-1 (SATB1). SATB1 is a nuclear-matrix-bi -Abstract Truncated-